Breast conservation treatment in women with locally advanced breast cancer – Experience from a single centre
Authors:
- V. ParmarVPV. Parmar
- A. KrishnamurthyAKA. Krishnamurthy
- R. HawaldarRHR. Hawaldar
- M.S. NadkarniMNM.S. Nadkarni
- R. SarinRSR. Sarin
- R. ChinoyRCR. Chinoy
- R. NairRNR. Nair
- K.A. DinshawKDK.A. Dinshaw
- R.A. BadweRBR.A. Badwe
- 1 January 2006
- journal article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 4 (2) , 106-114
Abstract
In absence of randomized evidence to support safety of conservative surgery (BCT) in locally advanced breast cancer (LABC), we analyzed a cohort of 664 women with LABC treated during January 1998 to December 2002 at Tata Memorial Hospital, Mumbai, India. All were treated with a multimodality regimen comprising of neoadjuvant chemotherapy (NACT) followed by surgery (modified radical mastectomy or BCT) and adjuvant radiotherapy and hormone therapy. The outcome was evaluated to assess safety of BCT. 71% (469/664) women responded to NACT (22% clinical CR and 49% PR) and 28.3% (188/664) underwent BCT. Positive lumpectomy margins were reported in 8.5%, with gross presence of tumor at the margins in 2.3% requiring a revision surgery. At a median follow-up of 30months, local relapse rate was 8% after BCT and 10.7% after mastectomy. The 3-year local DFS was better post-conservation than after mastectomy (87% vs 78%, P=0.02). The disease-free survival (DFS) was also superior after BCT, 72% vs 52% (P<0.001) at 3years and 62% vs 37% (P<0.001) at 5years respectively. On multivariate analysis, presence of lymphatic vascular emboli (LVE) was the major significant predictor of local recurrence (P<0.001, HR 2.52, 95% CI 1.52-4.18). DFS was better after BCT [(P<0.001, HR 2.0 (95% CI 1.38-2.91)]; shorter DFS was noted in LVE positive (HR 1.54, P=0.007) and larger residual disease after NACT (HR 1.13, P=0.001). BCT is technically feasible and safe post neo-adjuvant chemotherapy in women with LABC with no detriment in outcome.Keywords
This publication has 18 references indexed in Scilit:
- Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survivalBreast Cancer Research and Treatment, 2005
- Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer*Journal of Surgical Oncology, 2002
- Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancerBritish Journal of Cancer, 2000
- The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapyCancer, 2000
- Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management.Surgery Today, 2000
- Incidence and Impact of Documented Eradication of Breast Cancer Axillary Lymph Node Metastases Before Surgery in Patients Treated With Neoadjuvant ChemotherapyAnnals of Surgery, 1999
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999
- Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-upAnnals of Oncology, 1999
- Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancerRadiotherapy and Oncology, 1997
- Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer, 1988